Connect Biopharma Holdings (Connect Biopharma Holdings) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Debt-to-Equity?

Connect Biopharma Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.29 Mil. Connect Biopharma Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.18 Mil. Connect Biopharma Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $101.04 Mil. Connect Biopharma Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Connect Biopharma Holdings's Debt-to-Equity or its related term are showing as below:

CNTB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.01
Current: 0.01

During the past 5 years, the highest Debt-to-Equity Ratio of Connect Biopharma Holdings was 0.01. The lowest was 0.00. And the median was 0.00.

CNTB's Debt-to-Equity is ranked better than
99.91% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs CNTB: 0.01

Connect Biopharma Holdings Debt-to-Equity Historical Data

The historical data trend for Connect Biopharma Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Debt-to-Equity Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				-	-	-	0.01	0.01

Competitive Comparison of Connect Biopharma Holdings's Debt-to-Equity

For the Biotechnology subindustry, Connect Biopharma Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Debt-to-Equity falls into.

Connect Biopharma Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Connect Biopharma Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.285	+	0.18)	/	101.043
	=	0.00

Connect Biopharma Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.285	+	0.18)	/	101.043
	=	0.00

Connect Biopharma Holdings (NAS:CNTB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Connect Biopharma Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.